Henan Lingrui Pharmaceutical Future Growth

Future criteria checks 2/6

Henan Lingrui Pharmaceutical is forecast to grow earnings and revenue by 11.5% and 15.5% per annum respectively while EPS is expected to grow by 11.3% per annum.

Key information

11.5%

Earnings growth rate

11.3%

EPS growth rate

Pharmaceuticals earnings growth	18.3%
Revenue growth rate	15.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Oct 2023

Recent future growth updates

No updates

Recent updates

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 04

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Feb 29

Earnings and Revenue Growth Forecasts

SHSE:600285 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	4,518	746	N/A	787	1
12/31/2024	3,963	641	N/A	688	1
3/31/2024	3,432	614	756	777	N/A
12/31/2023	3,311	568	792	813	N/A
9/30/2023	3,232	526	847	865	N/A
6/30/2023	3,200	512	904	924	N/A
3/31/2023	3,108	479	805	830	N/A
12/31/2022	3,002	465	808	835	N/A
9/30/2022	2,917	440	654	696	N/A
6/30/2022	2,841	412	574	622	N/A
3/31/2022	2,786	396	637	707	N/A
12/31/2021	2,694	362	769	846	N/A
9/30/2021	2,635	383	663	741	N/A
6/30/2021	2,513	368	688	768	N/A
3/31/2021	2,430	346	460	536	N/A
12/31/2020	2,332	325	379	451	N/A
9/30/2020	2,215	302	367	424	N/A
6/30/2020	2,163	288	336	387	N/A
3/31/2020	2,068	270	386	428	N/A
12/31/2019	2,157	294	391	450	N/A
9/30/2019	2,149	292	442	479	N/A
6/30/2019	2,118	280	447	493	N/A
3/31/2019	2,078	270	413	460	N/A
12/31/2018	2,053	243	384	436	N/A
9/30/2018	2,139	240	319	420	N/A
6/30/2018	2,120	230	223	356	N/A
3/31/2018	1,990	223	27	201	N/A
12/31/2017	1,849	217	N/A	106	N/A
9/30/2017	1,697	198	N/A	18	N/A
6/30/2017	1,608	381	N/A	52	N/A
3/31/2017	1,513	364	N/A	107	N/A
12/31/2016	1,439	346	N/A	63	N/A
9/30/2016	1,315	365	N/A	113	N/A
6/30/2016	1,225	152	N/A	100	N/A
3/31/2016	1,133	141	N/A	110	N/A
12/31/2015	1,085	132	N/A	225	N/A
9/30/2015	1,006	119	N/A	251	N/A
6/30/2015	936	115	N/A	203	N/A
3/31/2015	901	97	N/A	173	N/A
12/31/2014	826	76	N/A	124	N/A
9/30/2014	802	75	N/A	130	N/A
6/30/2014	757	65	N/A	129	N/A
3/31/2014	718	59	N/A	130	N/A
12/31/2013	687	105	N/A	127	N/A
9/30/2013	662	103	N/A	88	N/A
6/30/2013	617	103	N/A	46	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600285's forecast earnings growth (11.5% per year) is above the savings rate (2.9%).

Earnings vs Market: 600285's earnings (11.5% per year) are forecast to grow slower than the CN market (24.3% per year).

High Growth Earnings: 600285's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600285's revenue (15.5% per year) is forecast to grow faster than the CN market (14.6% per year).

High Growth Revenue: 600285's revenue (15.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 600285's Return on Equity is forecast to be high in 3 years time

Henan Lingrui Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.24 in 3Q 2022)

Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 2Q 2022)

Now 22% undervalued

First quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.22 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.18 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥7.91

New 90-day low: CN¥8.09

New 90-day low: CN¥9.11

New 90-day low: CN¥9.28

Third quarter earnings released

New 90-day low: CN¥9.88

Earnings released

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies